Regulation & Power
Korea’s biotech bet shows how AI-era industrial policy is moving beyond chips
Seoul’s K-HERO program has picked CHA Biotech for a ₩31.5B, 3.5-year push in cell and gene therapy. The move ties Korea’s AI industrial policy to regulated bio data and manufacturing—raising cross-border, compute, and market access stakes.